Mason & Associates Inc Amgen Inc Transaction History

Mason & Associates Inc

$398 Million
Q3 2024

A detailed history of Mason & Associates Inc transactions in Amgen Inc stock. As of the latest transaction made, Mason & Associates Inc holds 2,273 shares of AMGN stock, worth $601,185. This represents 0.18% of its overall portfolio holdings.

Number of Shares

2,273

Previous 2,063 10.18%

Holding current value

$601,185

Previous $644,000 13.66%

% of portfolio

0.18%

Previous 0.17%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	BUY	$309.38 - $337.38 $64,969 - $70,849	210 Added 10.18%	2,273 $732,000
Q2 2024 Jul 18, 2024	BUY	$262.75 - $319.31 $80,927 - $98,347	308 Added 17.55%	2,063 $644,000
Q1 2024 Apr 23, 2024	SELL	$268.87 - $324.56 $75,283 - $90,876	-280 Reduced 13.76%	1,755 $498,000
Q4 2023 Jan 16, 2024	SELL	$255.7 - $288.46 $80,034 - $90,287	-313 Reduced 13.33%	2,035 $586,000
Q3 2023 Oct 19, 2023	BUY	$218.65 - $271.46 $1,749 - $2,171	8 Added 0.34%	2,348 $631,000
Q2 2023 Jul 20, 2023	BUY	$214.27 - $253.37 $1,928 - $2,280	9 Added 0.39%	2,340 $519,000
Q1 2023 Apr 20, 2023	BUY	$225.79 - $275.2 $69,769 - $85,036	309 Added 15.28%	2,331 $563,000
Q4 2022 Jan 12, 2023	SELL	$229.03 - $291.01 $5,954 - $7,566	-26 Reduced 1.27%	2,022 $0
Q3 2022 Oct 20, 2022	BUY	$224.46 - $253.15 $8,978 - $10,126	40 Added 1.99%	2,048 $462,000
Q2 2022 Jul 26, 2022	BUY	$230.71 - $256.74 $1,614 - $1,797	7 Added 0.35%	2,008 $489,000
Q1 2022 Apr 19, 2022	BUY	$219.27 - $242.57 $187,695 - $207,639	856 Added 74.76%	2,001 $484,000
Q4 2021 Mar 18, 2022	BUY	$198.88 - $227.6 $227,717 - $260,602	1,145 New	1,145 $257,000

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mason & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mason & Associates Inc with notifications on news.

Account

Mason & Associates Inc Amgen Inc Transaction History